drugset / Trial / NCT07231419

Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy

NCT07231419

Phase 3 Recruiting 734 enrolled Vertex Pharmaceuticals Incorporated
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine in participants with pain associated with diabetic peripheral neuropathy (DPN).

Timeline

Start
2025-11-21
Primary completion
2027-04-06
Completion
2027-04-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Suzetrigine Small molecule Oral